Drugs / Clindamycin
Clindamycin
also known as
Clindamycin Phosphate · Dalacin C · Cleocin · Clindesse · DARE-BV1 · CDP · CLDM · cleocin (clindamycin) · +13 more
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | CLEOCIN | — | 1995-10-05 – 1998-03-02 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | CLEOCIN HYDROCHLORIDE | — | 1970-05-22 – 1988-04-14 | fda.gov ↗ |
| Approved | US (FDA) | CLEOCIN HYDROCHLORIDE | — | 1970-02-22 | fda.gov ↗ |
Trials 131 · started per year
today
US approved 1970
1
1
1
2
2
1
4
2
4
6
13
8
4
6
5
5
6
2
4
9
6
8
4
5
3
10
4
4
1969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05582434 | Feb 2024 → Jun 2025 overdue | acne | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04980170 | Nov 2021 → Mar 2022 | — | Jordan University Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT00503542 | Feb 2007 → Feb 2008 | vaginitis | Agency for Healthcare Research and Quality (AHRQ) | Completed | No outcome recorded |
| Phase 119 trials · 2 met primary | ||||||
| Phase 1 | NCT06673641 | May → Sep 2024 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05354050 | Nov 2020 | bacterial vaginosis | Daré Bioscience, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04198129 | Oct 2020 → Jan 2022 | infectious disease | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04321070 | Sep → Dec 2019 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04134273 | Mar → Sep 2019 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03653403 | Aug 2018 → Jun 2019 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05367479 | Jul 2018 → Jan 2020 | hypertensive disorder, morbid obesity | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 1 | NCT02475876 | Nov 2015 → Aug 2018 | gram-positive bacterial infections | Michael Cohen-Wolkowiez | Completed | No outcome recorded |
| Phase 1 | NCT02545452 | Sep 2015 → Mar 2016 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02578043 | Apr → Aug 2015 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01728363 | Jan 2013 → May 2015 | infectious disease | Phillip Brian Smith | Completed | No outcome recorded |
| Phase 1 | NCT01769235 | Nov 2012 → Sep 2013 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01769664 | Sep 2012 → Jun 2013 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01428466 | Nov 2010 → Feb 2011 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01132443 | May → Jun 2010 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT01929278 | Dec 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT01915758 | Nov 2008 → Feb 2009 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00836056 | Nov 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00836004 | Nov 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07504822 | Apr 2026 → Mar 2027 expected | acne | Yohanes Firmansyah, dr, MH, MM | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04118296 | Oct → Nov 2019 | acne | Sukma Skin Treatment | Completed | No outcome recorded |
| Phase 1/2 | NCT02593383 | Mar 2015 → Jul 2017 | acne | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT00361322 | Apr 2005 → Jan 2006 | acne | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 219 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT07267013 | Apr → Jul 2026 overdue | aortic disorder | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06120140 | Feb 2024 → May 2027 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 2 | NCT05926869 | Aug → Dec 2022 | acne | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| Phase 2 | NCT04892706 | Jun 2021 → Sep 2022 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04469075 | Jul 2020 → Jul 2026 overdue | glioblastoma, toxic dermatosis | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04039750 | Jul 2019 → Dec 2026 expected | appendicitis | Prisma Health-Upstate | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03935828 | Jun 2019 → Dec 2020 | chronic rhinosinusitis, poisoning | United States Naval Medical Center, San Diego | Withdrawn | No outcome recorded |
| Phase 2 | NCT03476941 | Apr 2019 → Oct 2020 | abscess | University of Iowa | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03257202 | Sep 2017 → Jan 2018 | — | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT03122457 | Jan 2017 → Jul 2018 | actinic keratosis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02730962 | Jun 2016 → Jan 2018 | prediabetes syndrome | University of Minnesota | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02366884 | Jul 2011 → Dec 2022 | neoplasm | Dr. Frank Arguello Cancer Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT01361269 | Jun → Sep 2011 | malaria | Zentopharm GmbH | Unknown | No outcome recorded |
| Phase 2 | NCT01464138 | Sep 2010 → Sep 2011 | malaria | Jomaa Pharma GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00730028 | Apr 2009 → Feb 2015 | staphylococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Mixed |
| Phase 2 | NCT00473083 | Jan 2009 → Dec 2012 | exanthem | British Columbia Cancer Agency | Completed | Missed primary |
| Phase 2 | NCT00713609 | Jun 2008 → Mar 2009 | acne | Stiefel, a GSK Company | Completed | Mixed |
| Phase 2 | NCT00332163 | Apr 2006 → Jan 2008 | colorectal cancer, exanthem, toxic dermatosis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00217451 | Jun 2002 → Mar 2003 | malaria | Albert Schweitzer Hospital | Completed | No outcome recorded |
| Phase 2/35 trials · 2 missed | ||||||
| Phase 2/3 | NCT07202052 | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04349410 | Apr → Sep 2020 | COVID-19 | The Camelot Foundation | Completed | No outcome recorded |
| Phase 2/3 | NCT00729937 | Apr 2009 → May 2013 | staphylococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Mixed |
| Phase 2/3 | NCT00823901 | Feb 2009 → Oct 2010 | rosacea | Massachusetts General Hospital | Completed | Missed primary |
| Phase 2/3 | NCT03033472 | ? → Dec 2017 | periapical periodontitis | Cairo University | Unknown | Missed primary |
| Phase 327 trials · 3 met primary | ||||||
| Phase 3 | NCT06841003 | Feb 2025 → Jun 2027 expected | abscess, appendicitis | Spaarne Gasthuis | Recruiting | No outcome recorded |
| Phase 3 | NCT06336824 | Jun 2024 → May 2025 overdue | staphylococcus aureus infection | Clinical Research Centre, Malaysia | Recruiting | No outcome recorded |
| Phase 3 | NCT05502380 | Sep 2022 → Dec 2024 overdue | bacterial infectious disease | Balgrist University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05164081 | Jan 2022 → Jan 2026 overdue | periprosthetic joint infection | Umeå University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04067531 | Aug 2020 → Aug 2021 | bacterial infectious disease | Skaraborg Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04370548 | Jun → Nov 2020 | bacterial vaginosis | Daré Bioscience, Inc. | Completed | Met primary |
| Phase 3 | NCT03081962 | Feb → Aug 2017 | — | Hospital General Universitario Elche | Unknown | No outcome recorded |
| Phase 3 | NCT02515305 | Jul 2015 → Apr 2016 | acne | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT02465632 | Apr → Nov 2015 | acne | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 3 | NCT03374176 | Mar 2014 → Jul 2016 | chronic periodontitis, type 2 diabetes mellitus | Centro Universitario de Tonalá | Completed | No outcome recorded |
| Phase 3 | NCT02210689 | Jan → Oct 2014 | bacterial vaginosis, vaginal discharge, vulvovaginitis | Actavis Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02479971 | Jan 2014 → Jun 2015 | — | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 3 | NCT01792804 | Dec 2013 → Mar 2020 | staphylococcus aureus infection | Heinrich-Heine University, Duesseldorf | Completed | Met primary |
| Phase 3 | NCT02005666 | Nov 2013 → Sep 2016 | acne | Zydus Lifesciences Limited | Completed | No outcome recorded |
| Phase 3 | NCT02314806 | Jan 2013 → Dec 2014 | breast cancer | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 3 | NCT01788384 | Jul → Dec 2012 | acne | Watson Laboratories, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01796665 | Feb 2012 → Feb 2013 | acne | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT01445301 | Sep 2011 → Aug 2012 | acne | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT01293643 | May 2010 → Jan 2011 | bacterial vaginosis, vulvovaginal candidiasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00889356 | Sep 2009 → Mar 2010 | bacterial vaginosis, candidiasis | Zodiac Produtos Farmaceuticos S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT00891982 | Apr → Jun 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 3 | NCT00838812 | Mar 2009 → Jan 2010 | acne | Igefarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT00694928 | May 2008 → Nov 2009 | infective vaginitis | Lumara Health, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00689117 | Apr 2008 → Apr 2009 | acne | Stiefel, a GSK Company | Completed | Mixed |
| Phase 3 | NCT01867164 | Dec 2007 → Dec 2008 | infective vaginitis | Janssen-Cilag, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT00214643 | Jun 2005 → Jul 2006 | malaria | Albert Schweitzer Hospital, Netherlands | Completed | No outcome recorded |
| Phase 3 | NCT00000640 | ? → Sep 1994 | HIV infectious disease, pneumocystosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 436 trials · 3 met primary · 2 missed | ||||||
| Phase 4 | NCT07561541 | Apr 2026 → Dec 2027 expected | diabetes mellitus | Texas Tech University Health Sciences Center, El Paso | Recruiting | No outcome recorded |
| Phase 4 | NCT07357103 | Mar 2026 → Mar 2029 expected | pneumocystosis | McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07474194 | Sep 2025 → Apr 2026 overdue | — | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 4 | NCT06494072 | Aug 2024 → May 2028 expected | — | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 4 | NCT05867654 | Jul 2024 → Nov 2025 overdue | osteomyelitis | University of Louisville | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06336629 | Nov 2023 → Jul 2024 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT06172010 | Apr 2023 → Mar 2027 expected | periprosthetic joint infection | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05398679 | Aug 2022 → Dec 2026 expected | infective endocarditis | Fundacion Clinic per a la Recerca Biomédica | Recruiting | No outcome recorded |
| Phase 4 | NCT05137119 | Feb 2022 → Dec 2028 expected | staphylococcus aureus infection | University of Melbourne | Recruiting | Mixed |
| Phase 4 | NCT04834310 | Apr 2021 → May 2024 | breast disorder, poisoning | University of California, Los Angeles | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT04035070 | Jan → Jun 2021 | dental pulp necrosis | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04580472 | Oct 2020 → Sep 2026 overdue | — | Carilion Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04573504 | Sep 2020 → Sep 2024 | — | Northwestern University | Unknown | No outcome recorded |
| Phase 4 | NCT03560232 | Jul 2018 → Feb 2020 | — | Mercy Health Ohio | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04516148 | May 2018 → Oct 2020 | skin infection | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03883269 | Mar 2018 → Jun 2019 overdue | acne | Centre for Human Drug Research, Netherlands | Recruiting | No outcome recorded |
| Phase 4 | NCT03478163 | Mar 2018 → May 2021 | endometritis, obstetric disorder | Cedars-Sinai Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01899690 | Jun 2016 → Aug 2017 | prosthesis-related infectious disease | Emory University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02309346 | Dec 2014 → Dec 2023 | uterine disorder | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 4 | NCT02058628 | Feb → Sep 2014 | acne | GlaxoSmithKline | Completed | Met primary |
| Phase 4 | NCT01448733 | Jul → Oct 2011 | acne | Zeichner, Joshua, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT01585129 | Sep 2010 → Jul 2014 | — | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01206348 | Sep 2010 → Jul 2011 | acne | Medicis Global Service Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01111994 | Nov 2009 → Mar 2010 | acne | Callender Center for Clinical Research | Unknown | No outcome recorded |
| Phase 4 | NCT00964223 | Jul → Nov 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00964366 | Jul → Aug 2009 | acne | Stiefel, a GSK Company | Completed | Missed primary |
| Phase 4 | NCT00926367 | May → Jun 2009 | acne | Stiefel, a GSK Company | Completed | Missed primary |
| Phase 4 | NCT01047189 | Mar → Oct 2009 | acne | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT00887484 | Feb → Jun 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00671749 | Dec 2007 → Aug 2008 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00841776 | Aug 2007 → Nov 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00807014 | Nov 2006 → Aug 2008 | acne | Stiefel, a GSK Company | Completed | Met primary |
| Phase 4 | NCT00377000 | Nov 2005 → Mar 2006 | acne | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00219570 | Jan → Jun 2005 | acne | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00160394 | Dec 2004 → Aug 2005 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00398658 | Mar 2002 → Dec 2004 | endophthalmitis | Shahid Beheshti University of Medical Sciences | Completed | Met primary |
| Phase not applicable18 trials · 1 met primary · 1 missed | ||||||
| — | NCT06702345 | Mar 2025 → Jul 2026 overdue | Clostridium difficile colitis | Leiden University Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT07836686 | Nov 2024 → Mar 2026 | dental pulp necrosis, pulpitis | Uşak University | Completed | No outcome recorded |
| — | NCT07123792 | Jun 2024 → May 2025 | periodontal disorder | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06787885 | May 2024 → May 2026 | pleural empyema | Fayoum University | Completed | No outcome recorded |
| — | NCT06158451 | Mar → Aug 2024 | periapical periodontitis | Cairo University | Unknown | No outcome recorded |
| — | NCT06068673 | Mar → Dec 2023 | nervous system disorder | Damanhour University | Completed | No outcome recorded |
| — | NCT03779295 | Nov 2018 → Jun 2019 | acneiform dermatitis | West Virginia University | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT03742908 | Jun 2018 → Oct 2021 | breast neoplasm | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT04818931 | Apr 2018 → Jun 2019 | breast cancer | CHU de Quebec-Universite Laval | Completed | Missed primary |
| — | NCT02196740 | Jun 2013 → Dec 2014 | periapical periodontitis | Lin Jiacheng | Unknown | No outcome recorded |
| — | NCT01722708 | Nov 2012 → Jul 2025 | bacterial vaginosis | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT01561703 | Mar 2012 → Dec 2013 | streptococcal sore throat | University of Missouri-Columbia | Completed | No outcome recorded |
| — | NCT01114516 | Mar 2010 → Mar 2013 | cervical incompetence | Northwestern University | Completed | Met primary |
| — | NCT01498744 | Feb 2010 → Feb 2013 | abscess, methicillin-resistant staphylococcus aureus infectious disease | Ann & Robert H Lurie Children's Hospital of Chicago | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00814905 | Nov 2008 → Jan 2012 | chorioamnionitis | United States Naval Medical Center, Portsmouth | Withdrawn | No outcome recorded |
| — | NCT00002064 | — | HIV infectious disease, cerebral toxoplasmosis | Palo Alto Medical Foundation | Completed | No outcome recorded |
| — | NCT00000717 | ? → Nov 1991 | HIV infectious disease, pneumocystosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00000674 | ? → Aug 1992 | HIV infectious disease, cerebral toxoplasmosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy104 trials | ||||||
| Phase 0 | NCT05849090 Comparator | Mar 2023 → Dec 2024 | infectious disease | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT07663838 Comparator | Jun 2026 → Jan 2027 expected | bacterial vaginosis | Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06616168 Background | Sep 2023 → Aug 2026 overdue | bacterial vaginosis | Danylo Halytsky Lviv National Medical University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02595034 Comparator | Jan → Oct 2015 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01744730 Comparator | Jun 2013 → Aug 2014 | bacterial infectious disease, obesity disorder | Phillip Brian Smith | Completed | No outcome recorded |
| Phase 2 | NCT03723551 Comparator | Feb 2019 → Apr 2025 | bacterial infectious disease | Debiopharm International SA | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03578965 Background | Jul 2018 → Nov 2021 | low grade vulvar intraepithelial neoplasia, vulvar benign neoplasm | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT05166746 Comparator | Dec 2017 → Oct 2023 | bacterial vaginosis, female infertility | Peter Humaidan | Unknown | No outcome recorded |
| Phase 2 | NCT03234517 Background | Aug 2016 → Aug 2018 | bacterial vaginosis | Zagazig University | Unknown | No outcome recorded |
| Phase 2 | NCT02168816 Comparator | Mar 2014 → Feb 2017 | osteomyelitis | Loyola University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01874860 Background | Aug 2013 → Jul 2018 | colorectal cancer, head and neck cancer | University of Louisville | Completed | No outcome recorded |
| Phase 2 | NCT01757236 Comparator | Oct 2012 → Apr 2016 | periprosthetic joint infection | University Hospital, Tours | Unknown | No outcome recorded |
| Phase 2/3 | NCT07202091 Background | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06006663 Comparator | Aug → Oct 2023 | — | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05678621 Background | Nov 2022 → Apr 2027 expected | dysgammaglobulinemia, hematopoietic and lymphoid cell neoplasm | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01994993 Comparator | Dec 2013 → Jan 2017 | — | Michael Cohen-Wolkowiez | Completed | No outcome recorded |
| Phase 2/3 | NCT01400867 Background | Dec 2011 → May 2014 | primary bacterial infectious disease | Forest Laboratories | Completed | No outcome recorded |
| Phase 2/3 | NCT01127880 Comparator | Jul 2005 → Dec 2009 | hemopneumothorax | St. Luke's Hospital, Pennsylvania | Completed | No outcome recorded |
| Phase 3 | NCT07107477 Comparator | May 2025 → Sep 2027 expected | preterm premature rupture of the membranes | The Central and Eastern European Gynecologic Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT05074147 Background | May 2022 → Nov 2024 | osteomyelitis | Tourcoing Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT04723940 Comparator | Jan 2021 → Jan 2028 expected | periprosthetic joint infection | Rothman Institute Orthopaedics | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT04104178 Comparator | May 2020 → Sep 2025 | methicillin-resistant staphylococcus aureus infectious disease | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04194216 Comparator | May 2020 → Dec 2026 expected | nasal disorder | Stanford University | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT03945357 Comparator | May 2019 → Jan 2023 | — | Prisma Health-Upstate | Completed | No outcome recorded |
| Phase 3 | NCT03176134 Comparator | Jan 2019 → Jul 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03615768 Comparator | Aug 2018 → Feb 2020 | acne | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 3 | NCT02814916 Comparator | Mar 2017 → Jan 2024 | methicillin-resistant staphylococcus aureus infectious disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02809131 Comparator | Apr 2016 → Mar 2021 | sick sinus syndrome, systolic heart failure, third-degree atrioventricular block | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02276482 Comparator | Mar 2015 → Sep 2018 | skin disease caused by bacterial infection, skin infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02579161 Comparator | Sep 2014 → Mar 2018 | urolithiasis | Northwell Health | Completed | No outcome recorded |
| Phase 3 | NCT01915732 Comparator | Apr 2013 → Apr 2014 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01374581 Comparator | May 2012 → Jun 2014 | malaria | University of Antwerp | Completed | No outcome recorded |
| Phase 3 | NCT00911573 Comparator | Aug 2011 → May 2014 | infectious disease, skin disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT01138514 Comparator | Oct 2009 → Oct 2010 | acne | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT00776919 Comparator | Oct 2008 → Sep 2009 | acne | Stiefel, a GSK Company | Completed | Mixed |
| Phase 3 | NCT00616330 Comparator | Jan 2008 → Dec 2009 | vulvovaginitis | Lumara Health, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01125410 Comparator | Jan 2007 → Jul 2008 | bacterial vaginosis | Medinova AG | Completed | Met primary |
| Phase 3 | NCT00663286 Comparator | Oct 2006 → Aug 2007 | acne | Dow Pharmaceutical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00664248 Comparator | Oct 2006 → Aug 2007 | acne | Dow Pharmaceutical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00372294 Comparator | Jul 2005 → Aug 2008 | chorioretinitis | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT07392047 Comparator | Feb → Aug 2026 overdue | acne | Jinnah Postgraduate Medical Centre | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06422221 Comparator | Jul 2024 → Jan 2025 | bacterial infectious disease, endocarditis | University of Santiago de Compostela | Unknown | No outcome recorded |
| Phase 4 | NCT05899140 Comparator | Mar 2024 → Mar 2026 overdue | skin infection, staphylococcus aureus infection | Frieder Schaumburg | Recruiting | No outcome recorded |
| Phase 4 | NCT05846399 Comparator | Sep 2023 → Jul 2027 expected | cat-scratch disease | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 4 | NCT05206500 Background | May 2022 → Dec 2028 expected | urinary tract infection | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT04512638 Background | Jan 2021 → Oct 2025 | osteonecrosis of the jaw | Tim Van den Wyngaert | Unknown | No outcome recorded |
| Phase 4 | NCT04502095 Background | Sep 2020 → Mar 2025 | urinary bladder carcinoma, urinary tract infection | Roswell Park Cancer Institute | Completed | Met primary |
| Phase 4 | NCT05268835 Comparator | Feb 2020 → Aug 2022 | impacted teeth, multiple | Oral and Maxillofacial Surgery Clinic, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT03333408 Comparator | Jun 2018 → Dec 2024 | — | Our Lady of the Lake Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03261830 Comparator | Aug 2017 → Mar 2023 | — | Sumit Gupta | Completed | No outcome recorded |
| Phase 4 | NCT02860845 Comparator | Jul 2016 → Oct 2017 | bacterial vaginosis, candidiasis | Laboratorios Ordesa | Completed | No outcome recorded |
| Phase 4 | NCT03080740 Comparator | Jul 2016 → Jul 2017 | bacterial vaginosis | Guangzhou Yipinhong Pharmaceutical CO.,LTD | Unknown | No outcome recorded |
| Phase 4 | NCT02721173 Comparator | Apr → Dec 2016 | acne | All India Institute of Medical Sciences, Bhubaneswar | Completed | Met primary |
| Phase 4 | NCT02557399 Comparator | Oct → Dec 2015 | acne | GlaxoSmithKline | Completed | Met primary |
| Phase 4 | NCT02731105 Comparator | Feb 2015 → Feb 2017 | acne | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 4 | NCT02446782 Background | Jan 2015 → Apr 2016 | empyema, pleurisy | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 4 | NCT02018094 Comparator | Oct 2013 → Mar 2014 | skin infection | Hull University Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT01876628 Comparator | Oct 2013 → Dec 2015 | cellulitis | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT01951768 Comparator | Sep 2013 → Jun 2016 | ulcer of lower limbs | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 4 | NCT01800825 Comparator | Jul 2013 → Apr 2016 | bacterial vaginosis, pregnancy disorder | Christiana Care Health Services | Completed | No outcome recorded |
| Phase 4 | NCT02141217 Comparator | Mar → Dec 2013 | tooth disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01728376 Comparator | Nov 2012 → Jan 2016 | bacterial infectious disease | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01669980 Background | Oct 2012 → May 2014 | pneumonia | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT01422785 Comparator | Jul → Dec 2011 | acne | Zeichner, Joshua, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT01613092 Comparator | May 2011 → Nov 2013 | cardiac rhythm disease | Population Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01697826 Comparator | Apr → Sep 2011 | infective vaginitis | Dr Bharti Daswani | Completed | No outcome recorded |
| Phase 4 | NCT01231334 Comparator | Aug 2010 → Jun 2011 | acne | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01015638 Comparator | Aug → Sep 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00711802 Comparator | Jul 2008 → Oct 2013 | skin disease caused by bacterial infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00636935 Background | Feb 2008 → Aug 2013 | pneumocystosis | George Washington University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00837213 Comparator | Aug 2007 → Aug 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT01245322 Comparator | Jan 2007 → Oct 2014 | bacterial vaginosis | Skaraborg Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00352612 Comparator | Sep 2006 → May 2009 | abscess, folliculitis, staphylococcal infection | Aaron Chen | Completed | No outcome recorded |
| Phase 4 | NCT00642980 Comparator | Apr 2006 → Jun 2011 | pregnancy disorder | University Hospital, Lille | Completed | No outcome recorded |
| — | NCT07810244 Comparator | Oct 2026 → Jan 2027 expected | abscess, cellulitis | Nishtar Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07032883 Background | Jun 2025 → Feb 2026 overdue | female breast carcinoma | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT06207786 Background | Sep 2024 → May 2029 | epidermal appendage tumor, skin cancer | Mayo Clinic | Withdrawn | No outcome recorded |
| — | NCT07247851 Comparator | Jan → Jun 2024 | bacterial vaginosis | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| — | NCT05762484 Comparator | Apr 2023 → Dec 2024 | hidradenitis suppurativa | Erasmus Medical Center | Unknown | No outcome recorded |
| — | NCT06174909 Comparator | Nov 2022 → Aug 2023 | — | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT04631185 Background | May 2021 → Dec 2023 | — | The Plastic Surgery Foundation | Completed | No outcome recorded |
| — | NCT04751500 Comparator | Jan 2021 → Nov 2022 | — | Birmingham Women's and Children's NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT04438655 Background | May 2019 → Nov 2021 | — | University of Turin, Italy | Completed | No outcome recorded |
| — | NCT04093765 Background | Nov 2018 → Dec 2019 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| — | NCT03779360 Comparator | Oct 2018 → Feb 2019 | dermatitis | Centre for Human Drug Research, Netherlands | Completed | No outcome recorded |
| — | NCT03173053 Comparator | Feb 2018 → Oct 2021 | movement disorder, staphylococcus aureus infection | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT03412071 Comparator | Dec 2017 → Dec 2019 | — | University of Toronto | Unknown | No outcome recorded |
| — | NCT03326661 Comparator | Nov 2017 → Nov 2019 | peritonsillar abscess | Odense University Hospital | Unknown | No outcome recorded |
| — | NCT02674191 Background | May 2016 → Jun 2018 | — | Manal El Namrawy | Unknown | No outcome recorded |
| — | NCT02585141 Background | Oct 2015 → Jun 2020 | anal fistula | University of Southern Denmark | Completed | No outcome recorded |
| — | NCT02054676 Background | Feb 2014 → Apr 2016 | — | Lithuanian University of Health Sciences | Unknown | No outcome recorded |
| — | NCT01945450 Comparator | Jan 2014 → Sep 2016 | endometritis | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT01823523 Comparator | Jun 2013 → Oct 2015 | craniofacial and skeletal defects | Atlantic Center for Oral and Maxillofacial Surgery | Unknown | No outcome recorded |
| — | NCT01715610 Comparator | May 2012 → Nov 2015 | peritonsillar abscess | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01619410 Comparator | Jan 2012 → Dec 2016 | abscess, skin disease caused by bacterial infection | University of Chicago | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01235546 Comparator | May 2011 → Dec 2015 | abscess, endometritis, skin infection | Alan Tita | Completed | Met primary |
| — | NCT01237821 Comparator | Oct 2010 → Aug 2011 | acne | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| — | NCT01500837 Comparator | Oct 2010 → Oct 2011 | infective arthritis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT01063270 Comparator | Feb 2010 → Jul 2011 | hidradenitis suppurativa | Henry Ford Health System | Completed | No outcome recorded |
| — | NCT01155154 Comparator | Feb 2010 → Feb 2012 | — | State University of New York - Downstate Medical Center | Terminated | No outcome recorded |
| — | NCT01052246 Comparator | Oct 2008 → Jun 2009 | acne | Laserklinik Karlsruhe | Completed | No outcome recorded |
| — | NCT01044264 Comparator | Dec 2007 → Sep 2008 | acne | Padagis LLC | Completed | No outcome recorded |
| — | NCT00186082 Comparator | Sep 2003 → Jun 2006 | puerperal infection | Stanford University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2024-05-01 | Alembic Pharmaceuticals Ltd. | Regulatory Press Release USFDA Products Approval dated 9th May, 2024 alembicpharmaceuticals.com ↗
This is to inform the exchanges that the Company has received various US Food & Drug Administration (USFDA) (Tentative or Final) Product Approvals. |
| 2023-09-20 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1% zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1% (USRLD: Cleocin T Gel, 1%). |
| 2023-03-14 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg glenmarkpharma.com ↗
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg |
| 2022-08-11 | Impax Laboratories, LLC | Regulatory Amneal launches 4 new Generic products, including Vasopressin single-dose amneal.com ↗
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for four generics products, including vasopressin injection 1mL (single-dose). |
| 2021-10-06 | Cosette Pharmaceuticals, Inc. | Regulatory Solaris Pharma Receives Approval for First Generic Version of Clindagel® (clindamycin phosphate EQ 1%) cosettepharma.com ↗
This approval validates our stellar in-house development, regulatory and commercial capabilities, by not only getting timely Agency approval, but also by orchestrating a day-1 launch. |
| 2021-09-21 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1% glenmarkpharma.com ↗
Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin®1 Foam, 1%, of Mylan Pharmaceuticals Inc. |
| 2021-02-11 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Gel USP, 1% glenmarkpharma.com ↗
Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Gel USP, 1%, the generic version of Cleocin T®1 Gel, 1%, of Pharmacia & Upjohn. |
| 2019-06-20 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals receives tentative ANDA approval for Clindamycin Phosphate Foam, 1% glenmarkpharma.com ↗
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U .S. FDA) for Clindamycin Phosphate Foam, 1%, a generic version of EVOCLIN®1 Foam, 1%, of Mylan Pharmaceuticals Inc. |
| 2019-03-15 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5% glenmarkpharma.com ↗
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin and Benzoyl Peroxide Gel, 1%|5%, a generic version of BenzaClin®1 Gel, 1%|5%, of Valeant Bermuda. |
| 2018-12-29 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Clindamycin Phosphate and Benzoyl Peroxide Gel zyduslife.com ↗
Zydus Cadila has received the final approval from the USFDA to market Clindamycin Phosphate and Benzoyl Peroxide Gel, (US RLD – DUAC® Gel), 1.2%/ 5%. |
| 2018-07-17 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Clindamycin Phosphate Topical Solution USP zyduslife.com ↗
Zydus Cadila has received the final approval from the USFDA to market Clindamycin Phosphate Topical Solution USP ( Cleocin T), 1%. |
| 2015-03-26 | GlaxoSmithKline | Regulatory GSK receives approval for Encruse® Ellipta® in Japan for the treatment of COPD gsk.com ↗
The MHLW also today announced the approval of Duac® Combination Gel in Japan, for use in the treatment of acne vulgaris. |
All press releases naming this drug 21 releases
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 239 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clindamycin | “METHODS: This 16-week, two-center, investigator-blinded, randomized, parallel-group study evaluated the antimicrobial efficacy of clindamycin phosphate 1%/benzoyl peroxide 5%...” PMID 20214175 ↗ Feb 2010227“Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or...” NCT01728376 ↗ “To evaluate the safety and plasma pharmacokinetics (PK) of clindamycin and adapalene in IDP-126 Gel compared with that from Control Gel in subjects with moderate to severe acne...” NCT03653403 ↗ “This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv)...” NCT02168816 ↗ “OBJECTIVE: The aim of this study was to compare the efficacy and safety of clindamycin (1%) and benzoyl peroxide (5%) (CDP/BPO) gel once daily vs. clindamycin (1%) (CDP)...” PMID 27075705 ↗ Apr 2016 “Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗ “For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours, Cefuroxime 500 mg every 12 hours, Clarithromycin 500 mg every 6 hours,...” NCT03935828 ↗ “Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the...” NCT03176134 ↗ “women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days...” NCT01245322 ↗ “Patients will be randomized at the time of surgery to receive intravenous cefazolin or clindamycin (weight-based dosing) as a pre-operative antibiotic within 60 minutes of...” NCT05367479 ↗ “Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.” NCT02276482 ↗ |
| Known as | CDP | “OBJECTIVE: The aim of this study was to compare the efficacy and safety of clindamycin (1%) and benzoyl peroxide (5%) (CDP/BPO) gel once daily vs. clindamycin (1%) (CDP)...” PMID 27075705 ↗ Apr 2016 |
| Known as | CLDM | “CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).” NCT02557399 ↗ |
| Known as | Cleocin | “Cleocin is a trade name and the generic name is clindamycin.” NCT04198129 ↗1“Clindamycin, (Cleocin, Clindesse)” NCT05849090 ↗ |
| Known as | cleocin (clindamycin) | “cleocin (clindamycin)” NCT04194216 ↗ |
| Known as | Cleocin T | “Multiple topical applications of Cleocin T (clindamycin phosphate at a concentration equivalent to 10mg/mL) resulted in clindamycin serum levels ranging from 0 to 3 ng/mL.” NCT01132443 ↗ |
| Known as | CLINDA | “clindamycin (CLINDA) and trimethoprim-sulfamethoxazole (TMP-SMX)” NCT00730028 ↗ |
| Known as | Clindagel | “Topical application of Clindagel (clindamycin phosphate 1% gel) equivalent to 3 to 12 grams once daily for 5 days resulted in peak plasma clindamycin concentrations that were...” NCT01132443 ↗ |
| Known as | Clindamycin (Clindesse) | “Clindamycin (Clindesse)” NCT02168816 ↗ |
| Known as | Clindamycin generic; Brand Cleocin | “Clindamycin generic; Brand Cleocin” NCT01728363 ↗ |
| Known as | Clindamycin palmitate hydrochloride | “Clindamycin palmitate hydrochloride dispersible tablet” NCT03080740 ↗ |
| Known as | Clindamycin Phosphate | “Improvement of Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combination Gel” NCT03122457 ↗11“Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.” NCT00838812 ↗ “1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide” NCT01915732 ↗ “Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks” NCT03615768 ↗ “clindamycin phosphate \[equivalent to 1% clindamycin\]” NCT00807014 ↗ “Clindamycin phosphate 6 mg/1ml for injection” NCT03476941 ↗ “Drug: Clindamycin Phosphate” NCT04469075 ↗ |
| Known as | Clindamycin/Cleocin Pediatric | “Clindamycin/Cleocin Pediatric” NCT01561703 ↗ |
| Known as | Clindesse | “Reference Product: One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate...” NCT02210689 ↗1“Clindamycin, (Cleocin, Clindesse)” NCT05849090 ↗ |
| Known as | CLM | “AIMS: To investigate if vaginal application of dequalinium chloride (DQC, Fluomizin®) is as effective as vaginal clindamycin (CLM) in the treatment of bacterial vaginosis (BV).” PMID 22205034 ↗ Dec 2011 |
| Known as | CLN | “clindamycin (CLN); benzoyl peroxide (BPO); methylparaben-free (MPF)” NCT01132443 ↗ |
| Known as | Dalacin 300 mg | “women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days...” NCT01245322 ↗ |
| Known as | Dalacin C | “Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗2“Augmentin™ (amoxicillin + clavulanic acid) from GSK and Dalacin-C (clindamycin) from Pfizer will be used as study treatments.” NCT02141217 ↗ “Patients receiving 150mg of clindamycin (Dalacin C, Pfizer) after surgery every 8 hours” NCT05268835 ↗ |
| Known as | Dalacin T Gel | “Dalacin T Gel (clindamycin phosphate gel)” NCT00219570 ↗ |
| Known as | Dalacin vaginal cream 2% | “women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days...” NCT01245322 ↗ |
| Known as | DARE-BV1 | “This is a multicenter, randomized, double-blind, placebo-controlled study of DARE-BV1 (clindamycin phosphate vaginal gel, 2%) (QD x 1 day) compared to placebo vaginal gel (HEC...” NCT04370548 ↗1“Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).” NCT05354050 ↗ |
| Known as | XACIATO | “On March 31, 2022, Daré Bioscience, Inc and Organon & Co entered into an exclusive license agreement in which Organon obtained exclusive worldwide rights to develop,...” PMID 37098453 ↗ Apr 2023 |
| Action | Inhibit | “Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes.” NCT03779360 ↗ |
| Route | Oral | “two oral treatments for mild to moderate Pneumocystis carinii pneumonia (PCP): dapsone/trimethoprim or clindamycin/primaquine as compared to a standard treatment program of...” NCT00000640 ↗ |